Drug Trial Radar · NCT03940703
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Sep 19, 2019
Primary completion
May 11, 2023
Study completion Jul 15, 2026
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- May 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions
- Non-small Cell Lung Cancer
Interventions
TepotinibDrug
Participants were administered with Tepotinib orally once daily at a dose of 500 mg.
OsimertinibDrug
Participants received Osimertinib at a dose of 80 mg orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combined Therapy (Tepotinib+Osimertinib): Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version (NCI-CTCAE v 5.0)Time frame: Up to Day 21 of Cycle 1 (each Cycle is of 21 days)
- Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Fluorescence in Situ Hybridization(FISH)Time frame: Time from first administration of study treatment up to data cutoff (approximately assessed up to 42 months)
Locations
179 sites in 17 countries. Site status is shown where the registry gives one.
Yuma Regional Medical Center
Yuma, Arizona
Compassionate Care Research Group Inc - Edinger Medical Group, Inc.
Fountain Valley, California
Memorial Care
Long Beach, California
Ventura County Hematology Oncology Specialists
Oxnard, California
Innovative Clinical Research Institute
Whittier, California
Eastern Connecticut Hematology & Oncology Associates
Norwich, Connecticut
Holy Cross
Fort Lauderdale, Florida
Memorial Healthcare System
Hollywood, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Ocala Oncology
Ocala, Florida
University Cancer and Blood Center
Athens, Georgia
Hawaii Cancer Care
Honolulu, Hawaii
University of Chicago Medical Center
Chicago, Illinois
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana
Community Health Network
Indianapolis, Indiana
Beacon Health
South Bend, Indiana
Norton Cancer Institute
Louisville, Kentucky
Pontchartrain
Hammond, Louisiana
Medstar Franklin Square Clinical Research Center
Baltimore, Maryland
The Center for Cancer & Blood Disorders - Maryland
Bethesda, Maryland
Frederick Health- James M Stockman Cancer Institute
Frederick, Maryland
Boston Medical Center - Dept. Hematology/Oncology
Boston, Massachusetts
Southcoast Center for Cancer Care
Fairhaven, Massachusetts
Sparrow Hospital Herbert - Herman Cancer Center
Lansing, Michigan
Central Care Cancer Center (CCCC)
Bolivar, Missouri
St. Louis Cancer Care, LLP
Bridgeton, Missouri
Mosaic Life Care
Saint Joseph, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
New Jersey Cancer Care and Blood Disorders
Belleville, New Jersey
Summit Medical Group
Florham Park, New Jersey
NYU Langone Clinical Cancer Center - NYU Langone Medical Center
New York, New York
NYU Langone Clinical Cancer Center - NYU Langone Medical Cente
New York, New York
Weill Cornell Medical College - Gastroenterology
New York, New York
Southeastern Medical Oncology Center
Goldsboro, North Carolina
University Hospitals Seidman
Cleveland, Ohio
OhioHealth
Columbus, Ohio
Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma
Oregon Oncology Specialists
Salem, Oregon
Gettysburg Cancer Center
Gettysburg, Pennsylvania
Sanford Health
Sioux Falls, South Dakota
Showing 40 of 179 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.